Inspira Competitors

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

Celltrion is a fully integrated biopharmaceutical company dedicated to delivering innovative and affordable medications to improve patients’ access to advanced therapies. Pioneering monoclonal antibody (mAb) biosimilars, built on a legacy of trust, we are advancing antibody-based biologics to address unmet medical needs. Our end-to-end capabilities - from R&D to distribution - ensure efficiency, quality, and innovation at every stage, bringing life-changing therapies to patients worldwide. Partnering with purpose, we are committed to driving customer intimacy to co-creating value at every touchpoint across the care journey. #BuiltonTrustTowardInnovation For guidelines: https://bit.ly/4jv2wf2

혁신 신약개발을 향한 끊임없는 도전 종근당은 ‘세상에 없던 신약(First-in-Class)’과 ‘미충족 수요(Unmet Needs) 의약품’으로 난치병과 불치병, 희귀질환을 정복하여 국민의 삶의 질을 개선하고 인류의 건강에 기여하고 있습니다. 국내 최초 설립된 중앙연구소에서 오늘날 효종연구소에 이르기까지 최고 수준의 연구개발 투자로 최상의 인프라를 구축하고 있는 종근당. 신약은 물론 차별화된 기술에 우위를 둔 개량신약, 차세대 성장 동력이 될 바이오의약품까지 종근당의 혁신적인 신약 파이프라인은 세계를 향하고 있습니다. Dedicated to pharmaceuticals since its foundation, Chong Kun Dang has overcome many challenges,while continuing to grow and contribute to the advancement of Korea’s pharmaceutical industry. In the days when Korea imported 100% of the raw materials required for medicines from abroad, we built Korea’s largest plants for chemical synthesis and fermentation, making it possible to produce pharmaceutical ingredients locally using our own technology. From there, we had driven Korean Pharmaceutical Industry with this breakthrough on the path toward modernization. Furthermore, we became the first Korean pharmaceutical company to export products to the US market through the obtainment of the U.S. FDA approval. Now, on its 81st anniversary, we promise to put all efforts to lead continuous change and innovation, positioning Chong Kun Dang as a global pharmaceutical company with a competitive edge in the international market.